Show simple item record

dc.contributor.authorMitchell, Helen
dc.contributor.authorMorrissey, Diane
dc.date.accessioned2019-06-25T09:32:54Z
dc.date.available2019-06-25T09:32:54Z
dc.date.issued2019en
dc.identifier.citationMitchell H, Morrissey D. Intravenous versus subcutaneous trastuzumab: an economic and patient perspective. Br J Nurs. 2019;28(10):S15-S20.en
dc.identifier.pmid31116603en
dc.identifier.doi10.12968/bjon.2019.28.10.S15en
dc.identifier.urihttp://hdl.handle.net/10541/621892
dc.description.abstractSince 2005, when the first patients outside of a clinical trial were treated with trastuzumab at The Christie NHS Foundation Trust, a nurse-led service has been developed to facilitate and support a safe treatment pathway for patients. There have been significant developments in the number of patients treated, the mode of administration of the drug and patient choice regarding the location of treatment delivery. This article focuses on the change from intravenous to subcutaneous administration, considering patient experience and choice, particularly in light of the advent of biosimilar drugs, which will necessitate a return to the intravenous route. The relative costs of intravenous and subcutaneous administration are illustrated and the results of a patient survey presented, indicating a strong preference for subcutaneous trastuzumab.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.12968/bjon.2019.28.10.S15en
dc.titleIntravenous versus subcutaneous trastuzumab: an economic and patient perspectiveen
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, ManchesterBreast Care Nurse, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalBritish Journal of Nursingen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record